Ahmed Ahmed Allam, Heba A. Ahmed, Mohammad Ahmad Hassan, Safaa A. A. Khaled, Azza Shibl, Amira Mahmoud Osman, Nada Mohamed Rafat Ali, Nesma Mokhtar Ahmed
{"title":"程序性细胞死亡-1和程序性细胞死亡配体-1在儿童急性b淋巴细胞白血病中的表达及其作为生物标志物的意义。","authors":"Ahmed Ahmed Allam, Heba A. Ahmed, Mohammad Ahmad Hassan, Safaa A. A. Khaled, Azza Shibl, Amira Mahmoud Osman, Nada Mohamed Rafat Ali, Nesma Mokhtar Ahmed","doi":"10.1111/ijlh.14472","DOIUrl":null,"url":null,"abstract":"<div>\n \n \n <section>\n \n <h3> Introduction</h3>\n \n <p>This study aimed to assess programmed death-1 (PD-1) and programmed death ligand-1 (PDL-1) expression in newly diagnosed pediatric cases of acute B-lymphoblastic leukemia (B-ALL) and at 6 months of treatment and to explore their value as biomarkers.</p>\n </section>\n \n <section>\n \n <h3> Methods</h3>\n \n <p>Fifty newly diagnosed B-ALL patients and 30 controls were recruited. Bone marrow samples or peripheral blood were obtained from children at diagnosis and 6 months after cytotoxic therapy. Flow cytometric analysis of obtained samples was done and the PD-1, PDL-1, and CD3 (cluster of differentiation) expressions were recorded.</p>\n </section>\n \n <section>\n \n <h3> Results</h3>\n \n <p>Percentages of PD-1, PDL-1, and CD3 in the control and B-ALL groups at initial presentation were 7.9% ± 2.8% vs. 16.45% ± 7.7% (<i>p</i> = 0.023), 8.6% ± 3.4% vs. 19.05% ± 13.7% (<i>p</i> < 0.001), and 30.8% ± 1.2% vs. 11.05% ± 7.3% (<i>p</i> < 0.001), respectively. CD3 expression increased significantly at 6 months; PD-1 and PDL-1 expression showed insignificant decrease from initial presentation. There was a negative correlation between PD-1 and HB level (<i>p</i> = 0.03) and a positive correlation between PD-1 and PDL-1 at 6 months of treatment (<i>p</i> = 0.002). Remission rates increased significantly with the decrease of PD-1and PDL-1.</p>\n </section>\n \n <section>\n \n <h3> Conclusion</h3>\n \n <p>Initially, PD-1 and PDL-1 were higher in patients than in controls and decreased 6 months after treatment. PD-1 and PDL-1 expression was associated with increased remission rates, implicating that modulation of PD-1 and PDL-1 expression may be a therapeutic approach for B-ALL. Moreover, this study created a new method for the assessment of PD-1 and PDL-1 in B-ALL.</p>\n </section>\n \n <section>\n \n <h3> Clinical Trial</h3>\n \n <p>\n <b>Trial Registration:</b> NCT05428111</p>\n </section>\n </div>","PeriodicalId":14120,"journal":{"name":"International Journal of Laboratory Hematology","volume":"47 5","pages":"832-839"},"PeriodicalIF":2.3000,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Programmed Cell Death-1 and Programmed Cell Death Ligand-1 in Childhood Acute B-Lymphoblastic Leukemia: Expression and Significance as Biomarker\",\"authors\":\"Ahmed Ahmed Allam, Heba A. Ahmed, Mohammad Ahmad Hassan, Safaa A. A. Khaled, Azza Shibl, Amira Mahmoud Osman, Nada Mohamed Rafat Ali, Nesma Mokhtar Ahmed\",\"doi\":\"10.1111/ijlh.14472\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div>\\n \\n \\n <section>\\n \\n <h3> Introduction</h3>\\n \\n <p>This study aimed to assess programmed death-1 (PD-1) and programmed death ligand-1 (PDL-1) expression in newly diagnosed pediatric cases of acute B-lymphoblastic leukemia (B-ALL) and at 6 months of treatment and to explore their value as biomarkers.</p>\\n </section>\\n \\n <section>\\n \\n <h3> Methods</h3>\\n \\n <p>Fifty newly diagnosed B-ALL patients and 30 controls were recruited. Bone marrow samples or peripheral blood were obtained from children at diagnosis and 6 months after cytotoxic therapy. Flow cytometric analysis of obtained samples was done and the PD-1, PDL-1, and CD3 (cluster of differentiation) expressions were recorded.</p>\\n </section>\\n \\n <section>\\n \\n <h3> Results</h3>\\n \\n <p>Percentages of PD-1, PDL-1, and CD3 in the control and B-ALL groups at initial presentation were 7.9% ± 2.8% vs. 16.45% ± 7.7% (<i>p</i> = 0.023), 8.6% ± 3.4% vs. 19.05% ± 13.7% (<i>p</i> < 0.001), and 30.8% ± 1.2% vs. 11.05% ± 7.3% (<i>p</i> < 0.001), respectively. CD3 expression increased significantly at 6 months; PD-1 and PDL-1 expression showed insignificant decrease from initial presentation. There was a negative correlation between PD-1 and HB level (<i>p</i> = 0.03) and a positive correlation between PD-1 and PDL-1 at 6 months of treatment (<i>p</i> = 0.002). Remission rates increased significantly with the decrease of PD-1and PDL-1.</p>\\n </section>\\n \\n <section>\\n \\n <h3> Conclusion</h3>\\n \\n <p>Initially, PD-1 and PDL-1 were higher in patients than in controls and decreased 6 months after treatment. PD-1 and PDL-1 expression was associated with increased remission rates, implicating that modulation of PD-1 and PDL-1 expression may be a therapeutic approach for B-ALL. Moreover, this study created a new method for the assessment of PD-1 and PDL-1 in B-ALL.</p>\\n </section>\\n \\n <section>\\n \\n <h3> Clinical Trial</h3>\\n \\n <p>\\n <b>Trial Registration:</b> NCT05428111</p>\\n </section>\\n </div>\",\"PeriodicalId\":14120,\"journal\":{\"name\":\"International Journal of Laboratory Hematology\",\"volume\":\"47 5\",\"pages\":\"832-839\"},\"PeriodicalIF\":2.3000,\"publicationDate\":\"2025-04-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"International Journal of Laboratory Hematology\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://onlinelibrary.wiley.com/doi/10.1111/ijlh.14472\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q3\",\"JCRName\":\"HEMATOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"International Journal of Laboratory Hematology","FirstCategoryId":"3","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1111/ijlh.14472","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"HEMATOLOGY","Score":null,"Total":0}
Programmed Cell Death-1 and Programmed Cell Death Ligand-1 in Childhood Acute B-Lymphoblastic Leukemia: Expression and Significance as Biomarker
Introduction
This study aimed to assess programmed death-1 (PD-1) and programmed death ligand-1 (PDL-1) expression in newly diagnosed pediatric cases of acute B-lymphoblastic leukemia (B-ALL) and at 6 months of treatment and to explore their value as biomarkers.
Methods
Fifty newly diagnosed B-ALL patients and 30 controls were recruited. Bone marrow samples or peripheral blood were obtained from children at diagnosis and 6 months after cytotoxic therapy. Flow cytometric analysis of obtained samples was done and the PD-1, PDL-1, and CD3 (cluster of differentiation) expressions were recorded.
Results
Percentages of PD-1, PDL-1, and CD3 in the control and B-ALL groups at initial presentation were 7.9% ± 2.8% vs. 16.45% ± 7.7% (p = 0.023), 8.6% ± 3.4% vs. 19.05% ± 13.7% (p < 0.001), and 30.8% ± 1.2% vs. 11.05% ± 7.3% (p < 0.001), respectively. CD3 expression increased significantly at 6 months; PD-1 and PDL-1 expression showed insignificant decrease from initial presentation. There was a negative correlation between PD-1 and HB level (p = 0.03) and a positive correlation between PD-1 and PDL-1 at 6 months of treatment (p = 0.002). Remission rates increased significantly with the decrease of PD-1and PDL-1.
Conclusion
Initially, PD-1 and PDL-1 were higher in patients than in controls and decreased 6 months after treatment. PD-1 and PDL-1 expression was associated with increased remission rates, implicating that modulation of PD-1 and PDL-1 expression may be a therapeutic approach for B-ALL. Moreover, this study created a new method for the assessment of PD-1 and PDL-1 in B-ALL.
期刊介绍：
The International Journal of Laboratory Hematology provides a forum for the communication of new developments, research topics and the practice of laboratory haematology.
The journal publishes invited reviews, full length original articles, and correspondence.
The International Journal of Laboratory Hematology is the official journal of the International Society for Laboratory Hematology, which addresses the following sub-disciplines: cellular analysis, flow cytometry, haemostasis and thrombosis, molecular diagnostics, haematology informatics, haemoglobinopathies, point of care testing, standards and guidelines.
The journal was launched in 2006 as the successor to Clinical and Laboratory Hematology, which was first published in 1979. An active and positive editorial policy ensures that work of a high scientific standard is reported, in order to bridge the gap between practical and academic aspects of laboratory haematology.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
